Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Biomaterials ; 292: 121940, 2023 01.
Article in English | MEDLINE | ID: mdl-36493714

ABSTRACT

Intraperitoneal adhesions (IAs) are a major complication arising from abdominal repair surgeries, including hernia repair procedures. Herein, we fabricated a composite mesh device using a macroporous monofilament polypropylene mesh and a degradable elastomer coating designed to meet the requirements of this clinical application. The degradable elastomer was synthesized using an organo-base catalyzed thiol-yne addition polymerization that affords independent control of degradation rate and mechanical properties. The elastomeric coating was further enhanced by the covalent tethering of antifouling zwitterion molecules. Mechanical testing demonstrated the elastomer forms a robust coating on the polypropylene mesh does not exhibit micro-fractures, cracks or mechanical delamination under cyclic fatigue testing that exceeds peak abdominal loads (50 N/cm). Quartz crystal microbalance measurements showed the zwitterionic functionalized elastomer further reduced fibrinogen adsorption by 73% in vitro when compared to unfunctionalized elastomer controls. The elastomer exhibited degradation with limited tissue response in a 10-week murine subcutaneous implantation model. We also evaluated the composite mesh in an 84-day study in a rabbit cecal abrasion hernia adhesion model. The zwitterionic composite mesh significantly reduced the extent and tenacity of IAs by 94% and 90% respectively with respect to uncoated polypropylene mesh. The resulting composite mesh device is an excellent candidate to reduce complications related to abdominal repair through suppressed fouling and adhesion formation, reduced tissue inflammation, and appropriate degradation rate.


Subject(s)
Polypropylenes , Surgical Mesh , Rabbits , Mice , Animals , Surgical Mesh/adverse effects , Adhesives , Elastomers , Absorbable Implants , Tissue Adhesions/prevention & control , Tissue Adhesions/etiology , Hernia/prevention & control
2.
Nat Commun ; 12(1): 1367, 2021 03 01.
Article in English | MEDLINE | ID: mdl-33649338

ABSTRACT

Effective control of pain management has the potential to significantly decrease the need for prescription opioids following a surgical procedure. While extended release products for pain management are available commercially, the implementation of a device that safely and reliably provides extended analgesia and is sufficiently flexible to facilitate a diverse array of release profiles would serve to advance patient comfort, quality of care and compliance following surgical procedures. Herein, we review current polymeric systems that could be utilized in new, controlled post-operative pain management devices and highlight where opportunities for improvement exist.


Subject(s)
Drug Delivery Systems , Pain Management , Pain, Postoperative/drug therapy , Polymers/chemistry , Analgesics/administration & dosage , Analgesics/therapeutic use , Animals , Humans , Social Control, Formal
3.
J Control Release ; 329: 316-327, 2021 01 10.
Article in English | MEDLINE | ID: mdl-33278481

ABSTRACT

Medical prescriptions for the alleviation of post-surgical pain are the most abundant source of opioids in circulation. As a systemic drug delivery source, opioids leave patients at high risk for side effects after being dosed. Given the significant rate of unauthorized use, distribution, addiction, and opioid related deaths, an alternative method of post-surgical analgesia is needed. Herein, we report the use of bio-resorbable poly(ester urea) (PEU) films that controllably deliver a non-opioid COX-2 inhibitor, etoricoxib, in vivo and in vitro as a model system for post-surgical pain control. PEU composition, drug-load, and film thickness were varied to selectively control etoricoxib elution. Elution data were fit to a Higuchi model, and the diffusion constant of etoricoxib was calculated in each of the films. Pharmacokinetic (pK) data from an in vivo rat model showed the local tissue concentration of etoricoxib at the study endpoint to be up to 23-fold higher in tissue then plasma. In a well-established mouse model of diabetic neuropathic pain in vivo film implantation showed effective relief of pain for more than 4 days post-implantation and efficacious local etoricoxib delivery. Overall, implementation of local drug delivery systems such as this could reduce the need for opioid prescriptions associated with current pain management strategies.


Subject(s)
Esters , Urea , Animals , Cyclooxygenase 2 Inhibitors/therapeutic use , Delayed-Action Preparations/therapeutic use , Double-Blind Method , Esters/therapeutic use , Etoricoxib/therapeutic use , Humans , Mice , Pain, Postoperative/drug therapy , Pyridines/therapeutic use , Rats , Sulfones/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...